Drugs / Cinobufacini Tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02871869 | Sep 2016 → Sep 2018 | diffuse large B-cell lymphoma | Xinjiang Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cinobufacini Tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02871869 ↗ |
| Route | Oral | “0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities” NCT02871869 ↗ |